This is the online version of Adam’s Biotech Scorecard, a subscriber-only newsletter. STAT+ subscribers can sign up here to get it delivered to their inbox.

Morning! Lots in biotech today…. New priority review vouchers from the FDA, Mark Cuban rolls out a biosimilar deal, and a patient death is reported in Intellia’s CRISPR trial.

Trump’s priority review vouchers and a GLP-1 deal

The Food and Drug Administration issued a second round of “ Commissioner’s National Priority Vouchers ,” giving companies speedier reviews for drugs deemed aligned with U.S. priorities. This time, they’re tied to the Trump administration deals with Eli Lilly and Novo Nordisk to cut prices on blockbuster weight loss drugs.

To read the rest of this story subscribe to STAT+. Subscribe Log In

See Full Page